S

an Diego’s Neurocrine Biosciences on Tuesday just snagged a long-awaited Food and Drug Administration approval for its dopamine-regulating drug, Ingrezza, to treat a movement disorder called tardive dyskinesia. It’s the first drug approved to treat this disorder — and the first drug approved for the company, whose value has swelled past $3.6 billion.

Patients with conditions like bipolar disorder, schizophrenia, and major depression often get prescribed antipsychotic drugs — and tardive dyskinesia shows up as a rather debilitating side effect in about 5 to 8 percent of these people. It consists of uncontrollable, uncoordinated movements of the arms, hands, feet, body — or in facial expressions, such as grimacing, or constant movement of the jaw, tongue, lips, or eyebrows.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.